Van Herk Ventures

Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors.

SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.

Sensara B.V., based in Rotterdam, the Netherlands, focuses on home healthcare solutions through its product, Sensara HomeCare. The company aims to empower senior citizens and vulnerable individuals to maintain their independence while ensuring safety and health. Utilizing self-learning algorithms, Sensara monitors medically verified profiles through data collected from sensors, which is then communicated via user-friendly applications and interfaces. This system alerts family members and caregivers when assistance is needed, promoting proactive care. Sensara's modular product line seamlessly integrates solutions for various living situations, including independent, assisted, and nursing home environments. The company prioritizes data privacy, allowing clients to maintain control over their personal information, while emphasizing that understanding an individual’s history can enhance future care.

SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.

Ceradis B.V. is a company that specializes in the development and marketing of environmentally friendly solutions for plant nutrition and crop protection products. Founded in 2005 and based in Wageningen, the Netherlands, with an additional office in Bogotá, Colombia, Ceradis also offers crop formulation services. The company's products feature patented formulations that ensure optimal activity of ingredients and provide excellent handling characteristics for users. Ceradis serves the agricultural industry both in the Netherlands and on an international scale.

Medis is a provider of post-processing software for the quantification of cardiovascular images. Medis' mission is to empower medical professionals by providing software that gives them the facts.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Vastned is a retail property company headquartered in the Netherlands, specializing in the management and development of retail real estate in historic European cities. The company operates primarily through three segments: Premium City High Street Shops, High Street Shops, and Non-High Street Shops, which includes shopping centers, retail parks, retail warehouses, and supermarkets. Vastned's primary focus is on leasing properties to tenants in the fashion, dining, and retail sectors, generating most of its revenue from locations in the Netherlands, France, and Belgium. The company is committed to enhancing the appeal of its retail spaces by concentrating on high-quality locations that attract both consumers and premium brands.

Sensara B.V., based in Rotterdam, the Netherlands, focuses on home healthcare solutions through its product, Sensara HomeCare. The company aims to empower senior citizens and vulnerable individuals to maintain their independence while ensuring safety and health. Utilizing self-learning algorithms, Sensara monitors medically verified profiles through data collected from sensors, which is then communicated via user-friendly applications and interfaces. This system alerts family members and caregivers when assistance is needed, promoting proactive care. Sensara's modular product line seamlessly integrates solutions for various living situations, including independent, assisted, and nursing home environments. The company prioritizes data privacy, allowing clients to maintain control over their personal information, while emphasizing that understanding an individual’s history can enhance future care.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

VBHC is a professionally managed real estate company with marquee investors. They are privileged that India's largest home financer, Housing Development Finance Corporation (HDFC), is an anchor equity investor in VBHC.

DCPrime B.V. is a clinical-stage cancer immunotherapy company specializing in the development of therapeutic vaccines aimed at delaying or preventing cancer recurrence. Founded in 2005 and based in Leiden, the Netherlands, the company utilizes its proprietary DCOne technology platform to create vaccines that replicate the immune-stimulatory properties of patient-derived dendritic cell-based vaccines while offering the logistical advantages of off-the-shelf products. The DCOne platform enables the expression of various known tumor antigens, targeting multiple cancer types. As of December 2020, DCPrime operates as a subsidiary of Immunicum AB.

Isobionics is a biotechnology company specializing in the production of natural aroma ingredients for various markets, including food, beverage, flavor, and fragrance. Utilizing a proprietary fermentation process, Isobionics focuses on isoprenoid-based products, such as nootkatone and valencene, which are essential for creating high-quality flavors and fragrances. This innovative approach ensures that the ingredients are free from pesticides and seasonal variability, resulting in products that are both purer and more cost-effective. By delivering superior sensory experiences, Isobionics aims to meet the evolving needs of its customers across the food, beverage, oral care, and personal care industries.

Galapagos NV is a clinical-stage biotechnology company based in Mechelen, Belgium, that focuses on discovering, developing, and commercializing small molecule medicines. The company’s clinical programs include filgotinib, a JAK1 inhibitor undergoing trials for multiple conditions such as rheumatoid arthritis and Crohn’s disease, as well as GLPG1690, an autotaxin inhibitor in trials for idiopathic pulmonary fibrosis and systemic sclerosis. Additionally, Galapagos is developing GLPG1205, a GPR84 inhibitor for idiopathic pulmonary fibrosis, and GLPG1972 for osteoarthritis. The company also explores Toledo molecules for inflammation. Galapagos has established collaborations with several pharmaceutical companies, including Gilead Sciences and AbbVie. Founded in 1999, Galapagos aims to address diseases with high unmet medical needs and improve patient outcomes globally.

SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.

NightBalance B.V., established in 2009, is a medical technology company that develops innovative solutions to improve sleep quality. Originating from research at Delft University of Technology, the company specializes in creating a smart therapy device designed to treat positional obstructive sleep apnea. This medical device, the Sleep Position Trainer, measures a patient's sleep behavior and prevents apnea episodes, allowing users to achieve more comfortable and restful sleep.

VitalNext is a company that focuses on developing innovative life science technologies aimed at improving the health and well-being of the aging population. The company specializes in creating products with evidence-based health benefits, addressing the growing demand for solutions that support healthy aging as life expectancy increases. VitalNext's most advanced product is an innovative medical nutrition designed to improve body weight and muscle mass in malnourished individuals. These products are brought to market through distribution or licensing agreements with specialized business partners.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.

Agendia, Inc., established in 2003 and headquartered in Irvine, California, specializes in developing and distributing genomic-based diagnostic kits for cancer patients. The company's molecular diagnostic technology analyzes the complete human genome to provide physicians with crucial information about a patient's cancer, enabling personalized treatment plans. Agendia's breast cancer tests, for instance, help assess individual risk for metastasis and guide decisions on chemotherapy, hormonal therapy, or alternative treatments, thereby improving patient outcomes and reducing healthcare costs.